2015 ASCO AM Public Tuesday

Myeloma Oral Abstract session
Chicago, IL - 2015 ASCO Annual Meeting - Sagar Lonial, MD, presenting abstract LBA8512, Phase 2 study of daratumumab (DARA) monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). during Myeloma Oral Abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Tuesday, June 2, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
Myeloma Oral Abstract session
Chicago, IL - 2015 ASCO Annual Meeting - Sagar Lonial, MD, presenting abstract LBA8512, Phase 2 study of daratumumab (DARA) monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). during Myeloma Oral Abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Tuesday, June 2, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
Myeloma Oral Abstract session
Chicago, IL - 2015 ASCO Annual Meeting - Sagar Lonial, MD, presenting abstract LBA8512, Phase 2 study of daratumumab (DARA) monotherapy in patients with >3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius). during Myeloma Oral Abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Tuesday, June 2, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org
Myeloma Oral Abstract session
Chicago, IL - 2015 ASCO Annual Meeting - Sagar Lonial, MD, presenting Abstract 8508, ELOQUENT-2: A phase III, randomized, open-label study of lenalidomide (Len)/dexamethasone (dex) with/without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). during Myeloma Oral Abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Tuesday, June 2, 2015. Over 30,000 physicians, researchers and healthcare professionals from over 100 countries are attending the 51st Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Todd Buchanan 2015 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org

Powered by SmugMug